Sensitivities and specificities (in percentages) with 95% confidence intervals for MEWS, HOTEL and TOTAL at select cut-points (n = 302).

<p>Sensitivities and specificities (in percentages) with 95% confidence intervals for MEWS, HOTEL and TOTAL at select cut-points (n = 302).</p

Adjusted odds ratios for demographic and physiological variables used in the TOTAL score; n = 302.

*<p>The score for each component of TOTAL was obtained by rounding each regression coefficient to the nearest integer value. The TOTAL score ranges from 0 to 6.</p

Calculation of the Modified Early Warning Score (MEWS).

<p>Each component of MEWS has an associated score ranging from 0 to 3, based on the degree of derangement of the parameter. The total score is the sum of each component: the maximum possible score is 14.</p

Unadjusted odds ratios for demographic and physiological variables; n = 302.

<p>Unadjusted odds ratios for demographic and physiological variables; n = 302.</p

Patient characteristics on admission by outcome group; n = 302.

<p>SD, standard deviation; IQR, interquartile range.</p><p>t-tests were used to test differences between the alive and dead groups unless otherwise indicated;</p>*<p>Chi-squared test;</p>#<p>Mann-Whitney U test.</p

Additional file 1 of Critical care capacity and care bundles on medical wards in Malawi: a cross-sectional study

Additional file 1: Table S1. Wards Reporting Adequate Ability to Perform Key Critical Care Signal Functions

Outcomes according to study group.

<p>Groups: ____ No OI; …. TB; –– Other OIs.</p

Selected baseline characteristics by study groups.

<p>^a TB = tuberculosis; PTB = pulmonary tuberculosis; ETB = extrapulmonary tuberculosis.</p><p>^b p-values for categorical variables were obtained with the use of the chi-square test, while ANOVA test was used for continuous variables.</p><p>^c ZDV = zidovudine; 3TC = lamivudine; EFV = efavirenz; DDI = didanosine; TDF = tenofovir; FTC = emtricitabine.</p

Risk Factors of Time to Treatment Failure.

1<p>All adjusted models include treatment condition.</p><p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p

Baseline Participant Characteristics.

<p>Table Legend:</p><p>QOL_health: general health perceptions.</p><p>QOL_mental: mental health.</p><p>Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.</p><p>Treatment: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.</p><p>Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.</p